Researchers found that a simplified dosimetry calculation technique based on SPECT/CT scans from patients with metastatic prostate cancer undergoing 177Lu-PSMA-617 therapy enabled radiation absorbed dose estimation from a single imaging scan, with estimated tumor dose most accurate when scans were delayed for more than 72 hours. The findings in the Journal of Nuclear Medicine suggest that simplifying dosimetry approaches "would greatly assist in developing radiobiological models specific to Lu-PSMA, and other radionuclide therapies, allowing optimization of therapy for individual patients that are maximally effective and safe," said researcher Dr. John Violet.